Trial Profile
Treating neovascular age-related Macular Degeneration with Aflibercept: a pilot 24 month, multi- centre randomized controlled trial comparing Standard Care with an individualised Treat and Extend regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms MATE; The MATE study
- 24 May 2019 Planned End Date changed from 30 Sep 2016 to 1 Mar 2021.
- 24 May 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2016 Planned End Date changed from 1 Jun 2016 to 30 Sep 2016.